Pulmonx (STU:4NI) COGS-to-Revenue : 0.26 (As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Pulmonx COGS-to-Revenue?

Pulmonx's Cost of Goods Sold for the three months ended in Jun. 2024 was €5.09 Mil. Its Revenue for the three months ended in Jun. 2024 was €19.31 Mil.

Pulmonx's COGS to Revenue for the three months ended in Jun. 2024 was 0.26.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Pulmonx's Gross Margin % for the three months ended in Jun. 2024 was 73.65%.

Pulmonx COGS-to-Revenue Historical Data

The historical data trend for Pulmonx's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pulmonx COGS-to-Revenue Chart

Pulmonx Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.31

0.35

0.26

Pulmonx Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
COGS-to-Revenue	Get a 7-Day Free Trial															0.26	0.26	0.25	0.25	0.26

Pulmonx COGS-to-Revenue Calculation

Pulmonx's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	16.435	/	62.975
	=	0.26

Pulmonx's COGS to Revenue for the quarter that ended in Jun. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	5.087	/	19.307
	=	0.26

Pulmonx (STU:4NI) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Pulmonx's Gross Margin % for the three months ended in Jun. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	5.087 / 19.307
	=	73.65 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Pulmonx COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Pulmonx's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Pulmonx Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Pulmonx Corp (STU:4NI) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

LUNG:USA

Address

700 Chesapeake Drive, Redwood, CA, USA, 94063

Website

https://www.pulmonx.com

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). the company's solutions comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the U.S. and international markets.

Pulmonx Headlines

No Headlines